{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:06:05Z","timestamp":1793934365800,"version":"4.8.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT) in patients with refractory MAC lung disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least 6 months of stable GBT were randomly assigned (2:1) to receive ALIS with GBT (ALIS\u2009+\u2009GBT) or GBT alone. Once-daily ALIS was supplied in single-use vials delivering 590 mg amikacin to the nebulizer. The primary endpoint was culture conversion, defined as three consecutive monthly MAC-negative sputum cultures by Month 6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Enrolled patients (ALIS\u2009+\u2009GBT, n\u2009=\u2009224; GBT-alone, n\u2009=\u2009112) were a mean 64.7 years old and 69.3% female. Most had underlying bronchiectasis (62.5%), chronic obstructive pulmonary disease (14.3%), or both (11.9%). Culture conversion was achieved by 65 of 224 patients (29.0%) with ALIS\u2009+\u2009GBT and 10 of 112 (8.9%) with GBT alone (odds ratio, 4.22; 95% confidence interval, 2.08\u20138.57; P\u2009&amp;lt;\u20090.001). Patients in the ALIS\u2009+\u2009GBT arm versus GBT alone were more likely to achieve conversion (hazard ratio, 3.90; 95% confidence interval, 2.00\u20137.60). Respiratory adverse events (primarily dysphonia, cough, and dyspnea) were reported in 87.4% of patients receiving ALIS\u2009+\u2009GBT and 50.0% receiving GBT alone; serious treatment-emergent adverse events occurred in 20.2% and 17.9% of patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Addition of ALIS to GBT for treatment-refractory MAC lung disease achieved significantly greater culture conversion by Month 6 than GBT alone, with comparable rates of serious adverse events.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT02344004).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201807-1318oc","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T15:17:18Z","timestamp":1536938238000},"page":"1559-1569","source":"Crossref","is-referenced-by-count":359,"title":["Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by\n                    <i>Mycobacterium avium<\/i>\n                    Complex (CONVERT). A Prospective, Open-Label, Randomized Study"],"prefix":"10.1093","volume":"198","author":[{"given":"David E.","family":"Griffith","sequence":"first","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Tyler, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Eagle","sequence":"additional","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-171X","authenticated-orcid":false,"given":"Rachel","family":"Thomson","sequence":"additional","affiliation":[{"name":"University of Queensland, Gallipoli Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Aksamit","sequence":"additional","affiliation":[{"name":"Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Keio University Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen J.","family":"Addrizzo-Harris","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Hospital, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore K.","family":"Marras","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[{"name":"Host Defense Unit, Royal Brompton Hospital, and Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Morgan","sequence":"additional","affiliation":[{"name":"Concord Clinical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi R.","family":"Codecasa","sequence":"additional","affiliation":[{"name":"TB Reference Centre, Villa Marelli Institute\/Niguarda Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Royal Infirmary of Edinburgh and Queen\u2019s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Ruoss","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C.","family":"Ringshausen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hannover Medical School, and German Center for Lung Research, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Field","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie V.","family":"Philley","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Tyler, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard J.","family":"Wallace","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Tyler, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Coulter","sequence":"additional","affiliation":[{"name":"Queensland Mycobacterium Reference Laboratory, Pathology Queensland, Brisbane, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nezamis","sequence":"additional","affiliation":[{"name":"Insmed Incorporated, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[{"name":"OHSU-PSU School of Public Health, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,15]]},"reference":[{"key":"2026032023293777600_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"2026032023293777600_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3201\/eid1911.130737","article-title":"Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010","volume":"19","author":"Marras","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2026032023293777600_bib5","first-page":"977","article-title":"Pulmonary disease by non-tuberculous mycobacteria: clinical management, unmet needs and future perspectives","volume":"11","author":"Larsson","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"2026032023293777600_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-14-279","article-title":"A spatial epidemiological analysis of nontuberculous mycobacterial infections in Queensland, Australia","volume":"14","author":"Chou","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026032023293777600_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1164\/rccm.200905-0778OC","article-title":"Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors","volume":"181","author":"Andr\u00e9jak","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12879-018-3113-x","article-title":"High mortality in patients with Mycobacterium avium complex lung disease: a systematic review","volume":"18","author":"Diel","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2026032023293777600_bib9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1513\/AnnalsATS.201610-800OC","article-title":"Mortality after respiratory isolation of nontuberculous mycobacteria. A comparison of patients who did and did not meet disease criteria","volume":"14","author":"Novosad","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026032023293777600_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3201\/eid2303.161927","article-title":"Pulmonary nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001-2013","volume":"23","author":"Marras","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2026032023293777600_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201303-067OC","article-title":"A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan","volume":"11","author":"Morimoto","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026032023293777600_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"2026032023293777600_bib14","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026032023293777600_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.rmed.2017.08.031","article-title":"Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort","volume":"131","author":"Zweijpfenning","year":"2017","journal-title":"Respir Med"},{"key":"2026032023293777600_bib16","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/QCO.0b013e3283511a64","article-title":"Therapy of refractory nontuberculous mycobacterial lung disease","volume":"25","author":"Griffith","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2026032023293777600_bib18","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026032023293777600_bib19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib20","doi-asserted-by":"crossref","first-page":"e108703","DOI":"10.1371\/journal.pone.0108703","article-title":"Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection","volume":"9","author":"Rose","year":"2014","journal-title":"PLoS One"},{"key":"2026032023293777600_bib21","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1128\/AAC.00700-16","article-title":"Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats","volume":"60","author":"Malinin","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032023293777600_bib22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"2026032023293777600_bib23","article-title":"Randomized phase 3 trial of amikacin liposome inhalation suspension (ALIS) for treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in adult patients","volume-title":"Presented at the American Thoracic Society","author":"Griffith"},{"key":"2026032023293777600_bib24","first-page":"A1984","article-title":"Six-minute walk test (6MWT) performance in adult patients receiving amikacin liposome inhalation suspension (ALIS) for treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) [abstract]","volume":"197","author":"Winthrop","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib25","article-title":"NCT02628600: Open-label safety extension study assessing safety and tolerability of LAI in patients who participated in study INS-212 [accessed 2018 Nov 8]","author":"National Library of Medicine"},{"key":"2026032023293777600_bib26","article-title":"Pharmacokinetic evaluation of liposomal amikacin for inhalation in patients with treatment-refractory nontuberculous mycobacteria lung infection","volume-title":"Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17\u201321","author":"Rubino","year":"2015"},{"key":"2026032023293777600_bib27","doi-asserted-by":"crossref","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"2026032023293777600_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1164\/rccm.201704-0792LE","article-title":"Examining the effect of residual amikacin on sputum culture for nontuberculous mycobacteria","volume":"197","author":"Eagle","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib29","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"2026032023293777600_bib30","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"2026032023293777600_bib31","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1128\/AAC.01050-15","article-title":"Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients","volume":"59","author":"Modongo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032023293777600_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023293777600_bib33","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032023293777600_bib34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur Respir J"},{"key":"2026032023293777600_bib35","doi-asserted-by":"crossref","first-page":"E1062","DOI":"10.3390\/ijms18051062","article-title":"Inhaled antibiotic therapy in chronic respiratory diseases","volume":"18","author":"Maselli","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026032023293777600_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026032023293777600_bib37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2026032023293777600_bib38","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2026032023293777600_bib39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12879-017-2665-5","article-title":"The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases","volume":"17","author":"Yagi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2026032023293777600_bib40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2466-7-2","article-title":"Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series","volume":"7","author":"Davis","year":"2007","journal-title":"BMC Pulm Med"},{"key":"2026032023293777600_bib41","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s10096-011-1516-3","article-title":"Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis","volume":"31","author":"Safdar","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026032023293777600_bib42","doi-asserted-by":"crossref","first-page":"e00011","DOI":"10.1128\/AAC.00011-18","article-title":"Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032023293777600_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12890-016-0185-5","article-title":"Mycobacteria infect different cell types in the human lung and cause species dependent cellular changes in infected cells","volume":"16","author":"Ganbat","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2026032023293777600_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/jamp.2008.0693","article-title":"A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers","volume":"22","author":"Weers","year":"2009","journal-title":"J Aerosol Med Pulm Drug Deliv"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/198\/12\/1559\/67120989\/ajrccm_198_12_1559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/198\/12\/1559\/67120989\/ajrccm_198_12_1559.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:31:27Z","timestamp":1774063887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/198\/12\/1559\/8498469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,15]]},"published-print":{"date-parts":[[2018,12,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201807-1318oc","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734014923.793565560","asserted-by":"object"}]},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,12]]}}}